
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
This trial was for people with and also for people with acute myeloid leukaemia (AML) who between them had 2 and 3 out of 10 blood cells (20 to 30%) that were immature.
Cancer Research UK supported this trial.
Myelodysplastic syndrome (MDS) is a condition affecting the . If you have MDS, your bone marrow makes abnormal blood cells, but not enough healthy blood cells.
MDS can sometimes develop into acute myeloid leukaemia (AML). If you have a lot of abnormal cells in your bone marrow, there is a higher risk of the MDS becoming AML. Doctors may call this high risk MDS.
Doctors often treat high risk MDS with and antibiotics. This helps control the symptoms and fight infections that people with MDS might get. Doctors may call this ‘Best Supportive Care’ because it only improves the quality of life of people with MDS but does not treat their disease.
The researchers hoped that a new drug called decitabine may be able to help treat people with high risk MDS and AML.
The aims of this trial were to find out
We have contacted the trial team who tell us they don’t expect to be making results available for this trial.
The trial closed early. The trial team have told us that this was mainly due to poor recruitment and because decitabine was not a successful treatment in the few people who did join the trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Ghulam Mufti
Cancer Research UK
Janssen-Cilag
King's College London
Kings College Hospital NHS Foundation Trust
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/09/040.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”